Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

The regulation of nitrosamine impurities has been evolving rapidly due to concerns about their potential health risks, particularly their carcinogenicity. Regulatory authorities worldwide, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Therapeutic Goods
The detection of N-nitrosamine impurities in medicines and the increasing presence of nitrosamine drug substance-related impurities (NDSRIs) have presented significant challenges for both drug manufacturers and regulatory agencies.
Implementing effective strategies involves six crucial steps: conducting thorough risk assessments, optimizing manufacturing processes, using high-purity raw materials, performing rigorous analytical testing, adhering to regulatory guidelines, and maintaining continuous monitoring and quality control. These measures collectively minimize nitrosamine risks in
Discover the crucial steps pharmaceutical manufacturers must take to assess and mitigate nitrosamine risks in drug products. Learn how meticulous risk assessment, rigorous testing, and proactive strategies ensure product safety and global compliance. Read on to protect your patients and